PTC Therapeutics, Inc. (PTCT) analyst actions
Rating and price-target actions on PTCT in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the PTCT overview →
2 measured PTCT analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against PTC Therapeutics, Inc. (PTCT) And Encourages Shareholders to Reach Out | Press release | -0.09% | -2.06% | |
| CHMP Maintains Negative Opinion on Translarna™ Reexamination | Press release | +0.62% | +5.62% |
Keep exploring
More PTCT: earnings → · SEC filings → · PTCT overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Tyme Technologies, Inc. (TYME) | 691 | -0.28% | 41% |
| Marinus Pharmaceuticals, Inc. (MRNS) | 687 | 0.00% | 50% |
| Gilead Sciences, Inc. (GILD) | 677 | -0.00% | 50% |
| ONCOMED PHARMACEUTICALS (OMED) | 677 | -0.20% | 44% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.